• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Merck

Illumina, Merck launch test for cancer development, progression insights

June 22, 2022 By Sean Whooley

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK). The jointly developed test adds the assessment of a new genomic signature to the already distributed TruSight Oncology 500 assay, enabling researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous […]

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, News Well, Oncology Tagged With: Illumina, Merck

Baxter, 3M, Abbott near the top of Newsweek’s most responsible companies list

December 3, 2021 By Sean Whooley

Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of […]

Filed Under: Business/Financial News, Featured, News Well Tagged With: 3m, Abbott, Amerisource Bergen, Avanos Medical (formerly Halyard Health), Baxter, BD, Biogen, Boston Scientific, Cantel Medical Corp., Cardinal Health, Edwards Lifesciences, Gilead Sciences, Henry Schein, Hillrom, Hologic, Illumina Inc., Insulet, LabCorp, Merck, Pfizer, Quest Diagnostics Inc., ResMed, Thermo Fisher Scientific, Varex Imaging, Varian Medical Systems

FDA advisory committee votes in favor of COVID-19 pill molnupiravir

November 30, 2021 By Brian Buntz

FDA’s Antimicrobial Drugs Advisory Committee narrowly concluded that the benefits of Merck’s (NYSE:MRK) COVID-19 pill molnupiravir outweigh the risks. A total of 13 members of the panel voted in favor of the drug candidate, while 10 voted against it. There were no abstentions. Get the full story form our sister site, Drug Discovery & Development.

Filed Under: Featured, Pharmaceutical Tagged With: Merck, molnupiravir

Why Public Citizen is skeptical about the COVID-19 antiviral molnupiravir

November 30, 2021 By Brian Buntz

Dr. Michael Carome, director of Public Citizen’s health research group, is concerned about Merck’s SARS-CoV-2 antiviral molnupiravir. If it wins emergency use authorization (EUA), molnupiravir would be the first oral treatment for COVID-19. But Carome brought up several potential problems with molnupiravir during today’s public comment period of the FDA’s Antimicrobial Drugs Advisory Committee meeting. […]

Filed Under: Blog, Featured, Pharmaceutical Tagged With: COVID-19, Merck, molnupiravir, SARS-CoV-2

Xeris enters collaboration with Merck

October 25, 2021 By Sean Whooley

Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology. Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for engineering ultra-high concentration, ready-to-use formulations. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceutical Tagged With: Merck, Xeris Biopharma, xerispharmaceuticals

Early safety concerns accompanied Merck’s molnupiravir, the first potential oral COVID-19 therapy 

October 4, 2021 By Brian Buntz

The antiviral molnupiravir appears to be destined to become the first oral treatment for COVID-19. Merck and its partner Ridgeback Biotherapeutics intend to file for emergency use authorization after announcing that the drug appears to reduce the risk of hospitalization or death by about 50%. One potential hurdle for the drug is whether unvaccinated individuals […]

Filed Under: Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Merck, Ridgeback Biotherapeutics

Illumina, Merck partner on diagnostics for identifying specific cancer mutations

September 7, 2021 By Sean Whooley

Illumina (NSDQ:ILMN) and Merck today announced a partnership to develop diagnostics for identifying certain genetic mutations. The partnership aims to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD), leveraging Illumina’s TruSight Oncology 500 (TSO 500) content, enabling what the companies tout as the most comprehensive genomic […]

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, Oncology Tagged With: Illumina Inc., Merck

MedTech 100 roundup: Industry climbs again

June 21, 2021 By Sean Whooley

The medtech industry built off a strong performance two weeks ago with another uptick in the midst of an up-and-down year. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 18) at 110.64 points, producing a 0.9% rise from the 109.63-point mark set one week […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: Fractyl Health, Hologic, MedTech 100 Index, Merck, Organon

Merck spinoff Organon completes Alydia Health acquisition

June 16, 2021 By Sean Whooley

Merck (NYSE: MRK) spinoff Organon (NYSE:OGN) today announced the completion of its acquisition of Alydia Health for up to $240 million. Alydia Health develops treatments centered around preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. The company designed its Jada system to control and treat abnormal postpartum uterine […]

Filed Under: Business/Financial News, Featured, Gynecological, Mergers & Acquisitions, Women's Health Tagged With: alydiahealth, Merck, Organon

U.S. to buy nearly 2 million courses of Merck’s COVID-19 antiviral treatment

June 9, 2021 By Sean Whooley

Merck (NYSE:MRK) announced today that it agreed to supply the U.S. government with its molnupiravir (MK-4482) for treating COVID-19. Molnupiravir, developed through a collaboration between Merck and Ridgeback Biotherapeutics, is currently under evaluation in a Phase 3 clinical trial for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 infection and at least one risk factor […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Merck

10 of the best pharma companies to work for

May 26, 2021 By Brian Buntz

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, Biogen, Eisai, Janssen, Johnson & Johnson, Merck, Moderna, Novartis, Pfizer, Roche, Roche Pharmaceuticals, Sage Therapeutics

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy